72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)
Expertise includes: AL amyloidosis – clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.
Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Boston University School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.
Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.
Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.
She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.
Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.
- Associate Director, Amyloidosis Center, Boston University School of Medicine
- Member, BU-BMC Cancer Center, Boston University
- Director, Hematology & Medical Oncology, Stem Cell Transplantation Program, Boston Medical Center
- Secretary, International Society of Amyloidosis
- Executive committee, Amyloidosis Research Consortium
- Associate Editor, Amyloid: The Journal of Protein Folding disorders
- Seth G.S. Medical College, MBBS
- Published on 7/2/2020
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul 02; 136(1):71-80. PMID: 32244252.
- Published on 6/21/2020
Schulman A, Connors LH, Weinberg J, Mendelson LM, Joshi T, Shelton AC, Sanchorawala V. Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020 Jun 21. PMID: 32564450.
- Published on 6/19/2020
Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid. 2020 Jun 19; 1-6. PMID: 32551974.
- Published on 6/6/2020
Mendelson L, Shelton A, Brauneis D, Sanchorawala V. AL Amyloidosis in Myeloma: Red Flag Symptoms. Clin Lymphoma Myeloma Leuk. 2020 Jun 06. PMID: 32631780.
- Published on 6/1/2020
Kastritis E, Wechalekar A, Schönland S, Sanchorawala V, Merlini G, Palladini G, Minnema M, Roussel M, Jaccard A, Hegenbart U, Kumar S, Cibeira MT, Blade J, Dimopoulos MA. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. Br J Haematol. 2020 Jun 01. PMID: 32480420.
- Published on 5/13/2020
Cuddy SAM, Bravo PE, Falk RH, El-Sady S, Kijewski MF, Park MA, Ruberg FL, Sanchorawala V, Landau H, Yee AJ, Bianchi G, Di Carli MF, Cheng SC, Jerosch-Herold M, Kwong RY, Liao R, Dorbala S. Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease? JACC Cardiovasc Imaging. 2020 Jun; 13(6):1325-1336. PMID: 32417333.
- Published on 4/30/2020
Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020 Apr 30; 135(18):1541-1547. PMID: 31978210.
- Published on 4/3/2020
Sanchorawala V. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis. Acta Haematol. 2020 Apr 03; 1-7. PMID: 32248194.
- Published on 4/1/2020
Lerner G, Moradi S, Cohen-Bucay A, Chen H, Sanchorawala V, Gordon CE, Henderson JM. Coincidental crystalline light chain cast nephropathy, light chain proximal tubulopathy, and urine crystallopathy: A case report and review of the literature?. Clin Nephrol. 2020 Apr; 93(4):203-208. PMID: 31907143.
- Published on 3/10/2020
Staron A, Burks EJ, Lee JC, Sarosiek S, Sloan JM, Sanchorawala V. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. Blood Adv. 2020 Mar 10; 4(5):880-884. PMID: 32130406.
View 172 more publications: View full profile at BUMC